1. Home
  2. AQST

as 06-13-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Sympazan Oral Film, Suboxone Sublingual Film, Exservan Oral Film, and Zuplenz. The product pipeline includes Libervant Buccal Film, AQST-108, and AQST-305. The majority of its revenue comes from the United States.

Founded: 2004 Country:
United States
United States
Employees: N/A City: WARREN
Market Cap: 282.2M IPO Year: 2018
Target Price: $8.71 AVG Volume (30 days): 2.3M
Analyst Decision: Strong Buy Number of Analysts: 7
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.43 EPS Growth: N/A
52 Week Low/High: $1.25 - $6.23 Next Earning Date: 08-05-2024
Revenue: $51,502,000 Revenue Growth: 10.65%
Revenue Growth (this year): 0.41% Revenue Growth (next year): 17.61%

AQST Daily Stock ML Predictions

Stock Insider Trading Activity of Aquestive Therapeutics Inc. (AQST)

Name Ticker Relationship Date Transaction Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Schobel Alexander Mark AQST Chief Innovation/Tech Officer Mar 15 '24 Sell $6.00 50,000 $300,000.00 984,476 SEC Form 4

Share on Social Networks: